CINECA IRIS Institutional Research Information System

CHIRICOZZI, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.832
AS - Asia 2.133
EU - Europa 1.908
SA - Sud America 312
AF - Africa 196
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 4
Totale 11.393
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.668
CN - Cina 781
HK - Hong Kong 451
SG - Singapore 439
IT - Italia 423
GB - Regno Unito 330
BG - Bulgaria 299
BR - Brasile 272
SE - Svezia 245
VN - Vietnam 181
CI - Costa d'Avorio 146
RU - Federazione Russa 138
DE - Germania 135
CA - Canada 132
FI - Finlandia 91
TR - Turchia 80
JP - Giappone 55
AT - Austria 53
IN - India 45
FR - Francia 32
LT - Lituania 31
IE - Irlanda 27
MX - Messico 26
NL - Olanda 22
ES - Italia 18
SN - Senegal 17
IQ - Iraq 14
BD - Bangladesh 11
CH - Svizzera 11
ID - Indonesia 11
AR - Argentina 10
PL - Polonia 10
SA - Arabia Saudita 9
BJ - Benin 8
EG - Egitto 8
PH - Filippine 8
CO - Colombia 7
EC - Ecuador 7
HU - Ungheria 7
AU - Australia 6
KR - Corea 6
PK - Pakistan 6
RO - Romania 6
UA - Ucraina 6
UZ - Uzbekistan 6
ZA - Sudafrica 6
MA - Marocco 5
BE - Belgio 4
BO - Bolivia 4
GR - Grecia 4
JO - Giordania 4
MY - Malesia 4
VE - Venezuela 4
EU - Europa 3
KG - Kirghizistan 3
NP - Nepal 3
PE - Perù 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
BY - Bielorussia 2
CL - Cile 2
ET - Etiopia 2
GE - Georgia 2
IL - Israele 2
IR - Iran 2
KZ - Kazakistan 2
LB - Libano 2
MT - Malta 2
NZ - Nuova Zelanda 2
OM - Oman 2
PA - Panama 2
PT - Portogallo 2
PY - Paraguay 2
SK - Slovacchia (Repubblica Slovacca) 2
AO - Angola 1
AZ - Azerbaigian 1
BB - Barbados 1
CR - Costa Rica 1
CW - ???statistics.table.value.countryCode.CW??? 1
CZ - Repubblica Ceca 1
DZ - Algeria 1
HR - Croazia 1
JM - Giamaica 1
KH - Cambogia 1
LU - Lussemburgo 1
LV - Lettonia 1
NE - Niger 1
NO - Norvegia 1
RS - Serbia 1
UG - Uganda 1
UY - Uruguay 1
VG - Isole Vergini Britanniche 1
Totale 11.393
Salva come PNG Salva come JPEG
Città #
Fairfield 838
Ashburn 758
Woodbridge 678
Santa Clara 525
Houston 478
Hong Kong 449
Ann Arbor 432
Seattle 348
Chandler 307
Sofia 299
Cambridge 293
Wilmington 273
Shanghai 247
Beijing 228
Lancaster 227
Singapore 224
New York 202
Abidjan 145
Princeton 129
Boardman 113
Lawrence 111
Medford 107
Ottawa 101
Serra 99
Des Moines 90
Nanjing 61
Dong Ket 59
Istanbul 57
London 51
Los Angeles 45
San Diego 43
Florence 39
Guangzhou 39
Redwood City 34
Washington 33
Dearborn 31
Vienna 31
Phoenix 27
Munich 26
Frankfurt am Main 23
Milan 23
Siauliai 22
Düsseldorf 20
Nanchang 19
Rome 18
Tokyo 18
Dakar 17
Changsha 16
Chicago 16
Rio de Janeiro 15
Kunming 14
Turku 14
Jiaxing 13
São Paulo 13
Belo Horizonte 12
Hebei 11
Shenyang 11
Norwalk 10
Toronto 10
Bremen 9
Detroit 9
Hangzhou 9
Nuremberg 9
Cotonou 8
Atlanta 7
Bologna 7
Fuzhou 7
Porto Alegre 7
San Francisco 7
Baghdad 6
Brooklyn 6
Hefei 6
Jinan 6
Kent 6
Montreal 6
Oranmore 6
Pisa 6
Tashkent 6
Berlin 5
Cairo 5
Campinas 5
Council Bluffs 5
Dhaka 5
Esslingen am Neckar 5
Guadalajara 5
Guayaquil 5
Hanoi 5
Indiana 5
Izmir 5
Lucca 5
Mozzanica 5
Adana 4
Bareggio 4
Boston 4
Brasília 4
Brussels 4
Budapest 4
Charlotte 4
Chennai 4
Cuauhtémoc 4
Totale 8.826
Salva come PNG Salva come JPEG
Nome #
Trattamento topico delle dermatiti da contatto: validazione scientifica di una crema lenitiva a base di biotina, L-carnitina, pantenolo, α-bisabololo e tocoferolo. [Topical treatment of contact dermatitis with natural active principles] 222
Assessment of disease severity and treatment effectiveness in hidradenitis suppurativa 214
Sensors and Biosensors for C-Reactive Protein, Temperature and pH, and Their Applications for Monitoring Wound Healing: A Review 170
AISI: A New Disease Severity Assessment Tool for Hidradenitis Suppurativa 168
Potential correlation of wound bed score and biomarkers in chronic lower leg wounds: an exploratory study 159
Nanomedicine in dermatology: Benefits and emerging applications 151
Complete Resolution of Erythrodermic Psoriasis in an HIV and HCV Patient Unresponsive to Antipsoriatic Treatments after Highly Active Antiretroviral Therapy (Ritonavir, Atazanavir, Emtricitabine, Tenofovir). 143
The Quality of Life impairment in Hidradenitis Suppurativa 139
Crosstalk between skin inflammation and adipose tissue-derived products: pathogenic evidence linking psoriasis to increased adiposity. 138
Optimizing acitretin use in patients with plaque psoriasis 136
Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis 136
Alexithymia affects patients with hidradenitis suppurativa 136
A new therapeutic for the treatment of moderate to severe plaque psoriasis: apremilast 133
Deep pulse fractional CO2 laser combined with a radiofrequency system: results of a case series 133
Acne fulminans associated with lymecycline intake: A case report 130
TSLP-activated dendritic cells induce human T follicular helper cell differentiation through OX40-ligand 129
UVA-1 Laser in the Treatment of Palmoplantar Pustular Psoriasis 128
Apremilast for the treatment of psoriasis 127
Atopic dermatitis keratinocytes exhibit normal T(H)17 cytokine responses 125
A revolutionary therapeutic approach for psoriasis: bispecific biological agents. 124
Adalimumab in the treatment of plaque-type psoriasis and psoriatic arthritis. 123
Spotlight on dupilumab in the treatment of atopic dermatitis: Design, development, and potential place in therapy 123
Risankizumab for the treatment of moderate to severe psoriasis 123
Cutaneous human papillomaviruses as recurrence factor in actinic keratoses 121
Etanercept biosimilar SB4 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry 120
IL-6 as a druggable target in psoriasis: Focus on pustular variants 117
Long-Term Outcome of Adalimumab in a Young Girl with Hidradenitis Suppurativa 117
Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis 117
New insights in the pathogenesis of cutaneous autoimmune disorders. 116
Treatment of psoriasis with topical agents: Recommendations from a Tuscany Consensus 116
Hidradenitis Suppurativa Associated with Down Syndrome Is Characterized by Early Age at Diagnosis 116
Improvement of severe facial seborrheic dermatitis following low-dose isotretinoin therapy 116
Gene Expression Profiling Associated with the Progression of Classic Kaposi’s Sarcoma. 115
Pathogenic role of IL-17 in psoriasis and psoriatic arthritis 114
A new class of biologic agents facing the therapeutic paradigm in psoriasis: anti-IL-23 agents 114
Broad defects in epidermal cornification in atopic dermatitis identified through genomic analysis. 114
Relevance of in vitro 3-D skin models in dissecting cytokine contribution to psoriasis pathogenesis 113
Gynecomastia following isotretinoin treatment: a rare endocrine side effect 113
Increased expression of interleukin-17 pathway genes in nonlesional skin of moderate-to-severe psoriasis vulgaris 112
Scanning the immunopathogenesis of psoriasis 112
Profile of certolizumab and its potential in the treatment of psoriatic arthritis. 112
Tofacitinib for the treatment of moderate-to-severe psoriasis 111
Isotretinoin-triggered acne fulminans: a rare, disabling occurrence 111
Lasers and Energy Devices for the Skin: Conventional and Unconventional Use 111
Expression of IL-23/Th17-related cytokines in basal cell carcinoma and in the response to medical treatments 110
Current therapeutic paradigm in pediatric atopic dermatitis: Practical guidance from a national expert panel 110
Integrative responses to IL-17 and TNF-a in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. 109
Biomarkers for psoriasis skin lesions 109
Usefulness of QuantiFERON®-TB Gold test in psoriatic patients under treatment with tumour necrosis factor blockers. 108
Effective topical agents and emerging perspectives in the treatment of psoriasis. 108
The new era for the treatment of psoriasis and psoriatic arthritis: Perspectives and validated strategies. 107
Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response. 106
New topical treatments for psoriasis 106
Thymic stromal lymphopoietin links keratinocytes and dendritic cell-derived IL-23 in patients with psoriasis 106
Trattamento topico della xerosi cutanea severa: risultati di uno studio osservazionale. [Topical treatment of severe xerosis: Results of an observational study] 105
Small molecules and antibodies for the treatment of psoriasis: A patent review (2010–2015) 104
Role of IL-23 in the pathogenesis of psoriasis: a novel potential therapeutic target? 104
Quality of life of psoriatic patients evaluated by a new psychometric assessment tool: PsoDisk. 104
No meaningful association between suicidal behavior and the use of IL-17A-neutralizing or IL-17RA-blocking agents 104
Apheresis in the treatment of recalcitrant atopic dermatitis: Case series and review of the literature 102
Optimizing Anti-Inflammatory and Immunomodulatory Effects of Corticosteroid and Vitamin D Analogue Fixed-Dose Combination Therapy 102
A giant annular rash in a tuscanian woodman: the many faces of erythema chronicum migrans 102
IL-17 targeted therapies for psoriasis. 101
Granuloma annulare: A case treated with infliximab successfully 101
HIDRAdisk: an innovative visual tool to assess the burden of hidradenitis suppurativa 101
Golimumab in Patients Affected by Moderate to Severe Psoriatic Arthritis: An Open-Label Study in Thirty-Two Patients Previously Treated with Other Biologics 100
Biomolecular index of therapeutic efficacy in psoriasis treated by anti-TNF alpha agents 100
Real-life 9-year experience with adalimumab in psoriasis and psoriatic arthritis: Results of a single-centre, retrospective study 99
The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis 99
Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. 98
Efficacy and safety of Infliximab in psoriatic patients over the age of 65 98
Ustekinumab for treatment of plaque psoriasis in patient with Down Syndrome. 98
An occlusive dressing containing betamethasone valerate 0.1% for the treatment of prurigo nodularis 97
Emerging applications of nanomedicine in dermatology 96
Increased levels of IL-17 in tear fluid of moderate-to-severe psoriatic patients is reduced by adalimumab therapy 96
PsAPASH: A new syndrome associated with hidradenitis suppurativa with response to tumor necrosis factor inhibition 96
IL-17 Induces an Expanded Range of Downstream Genes in Reconstituted Human Epidermis Model. 95
Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris. 94
Unconventional Use of Intense Pulsed Light 93
Characterization of comorbid conditions burdening hidradenitis suppurativa: a multicentric observational study 93
Urticaria associated with hyper-IgE in a patient with psoriasis undergoing treatment with efalizumab. 92
Immunologic biomarkers for clinical and therapeutic management of psoriasis 92
Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: a report of two cases. 91
Genetic Markers for Cardiovascular Disease in Psoriasis: The Missing Piece. 90
Adipose tissue response to IL-17 combined with TNF-alpha exposure 90
Modulation of inflammatory gene transcripts in psoriasis vulgaris: Differences between ustekinumab and etanercept 88
European consensus statement on phenotypes of pustular psoriasis 87
Elderly psoriatic patients under biological therapies: an Italian experience 87
Dusky Red Swelling of the Penis in Association with Fever and Diarrhoea: A Quiz. 86
Potential role of serum amyloid A in hidradenitis suppurativa 86
Testing biologics and intracellular signaling inhibitors on pediatric atopic dermatitis: a stairway to modern therapeutic approaches 85
Un nuovo approccio fototerapico alle dermatosi croniche 85
The Hidradenitis Suppurativa (HS) “Multidisciplinary Unit”: a rationale and practical proposal for an organised clinical approach 85
Psoriasis Phenotype in Inflammatory Bowel Disease: A Case-Control Prospective Study 84
The management of moderate-to-severe chronic plaque psoriasis 84
Psoriasis 82
Use of Vitamins and their Derivates in the Treatment of Cutaneous Disorders. 79
Dermal CARD14 expression in psoriasis 77
Diabete mellito e malattie cutanee autoimmuni 77
HS-TIME: A Modified TIME Concept in Hidradenitis Suppurativa Topical Management 76
Totale 11.082
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.743
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34.743
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021818 66 59 50 48 44 54 37 51 84 77 43 205
2021/20221.112 23 42 46 65 230 159 21 81 42 16 45 342
2022/20231.155 159 166 80 62 110 117 16 83 258 5 82 17
2023/2024768 36 39 90 30 110 243 20 42 6 23 14 115
2024/20252.905 6 116 28 128 366 349 233 147 269 441 310 512
2025/202680 80 0 0 0 0 0 0 0 0 0 0 0
Totale 11.768